Mary Casebolt
Family · Cleveland, TXNPI 1588933774
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$914
- AstraZeneca$813
- Lilly USA, LLC$421
- Novo Nordisk$397
- AbbVie$310
- Otsuka America Pharmaceutical, Inc.$243
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 54 | $914 |
| AstraZeneca | 35 | $813 |
| Lilly USA, LLC | 28 | $421 |
| Novo Nordisk | 24 | $397 |
| AbbVie | 21 | $310 |
| Otsuka America Pharmaceutical, Inc. | 13 | $243 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $234 |
| Lundbeck LLC | 10 | $224 |
| Mylan Specialty L.p. | 10 | $223 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $150 |
| Pfizer | 9 | $144 |
| Galderma Laboratories, L.p. | 1 | $128 |
| Sunovion Pharmaceuticals Inc. | 10 | $126 |
| Sanofi-aventis U.S. LLC | 8 | $117 |
| Boehringer Ingelheim | 6 | $108 |
| Astellas Pharma US Inc | 5 | $99 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Amgen | 5 | $73 |
| Abbott | 3 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Exact Sciences | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Edwards Lifesciences | 1 | $41 |
| Bayer | 2 | $32 |
| Tactile Systems Technology Inc | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Viatris Specialty LLC | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$120
How this compares
$5,299 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $94,651 |
| RexultiBrexpiprazole | 55 | $81,238 |
| MounjaroTirzepatide | 41 | $61,476 |
| XifaxanRifaximin | 29 | $51,355 |
| FarxigaDapagliflozin Propanediol | 88 | $45,332 |
| JardianceEmpagliflozin | 42 | $33,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,521 |
| JanuviaSitagliptin Phosphate | 48 | $32,473 |
| EntrestoSacubitril/Valsartan | 37 | $22,171 |
| EliquisApixaban | 31 | $21,655 |
| XareltoRivaroxaban | 21 | $21,049 |
| GemtesaVibegron | 59 | $20,081 |
| MyrbetriqMirabegron | 24 | $14,993 |
| RybelsusSemaglutide | 15 | $14,341 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $397 | $108,993113 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $243 | $81,23855 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $421 | $73,29064 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $813 | $60,392118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $234 | $51,35529 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $914 | $46,04868 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $108 | $39,99554 claims |
| PfizerEliquis | $144 | $21,65531 claims |
| Johnson & JohnsonXarelto | $12 | $21,04921 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $64 | $20,08159 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $14,99324 claims |
| AbbVieLinzess | $310 | $6,94811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Cleveland
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.